可注射的长效莱纳卡巴维尔抗艾滋病毒暴露前预防 (PrEP) 的药理动力学,药理动力学,疗效和耐药性选择
medRxiv : the preprint server for health sciences
|September 5, 2025
概括
新的注射性艾滋病毒暴露前预防 (PrEP) 与莱纳卡巴维尔 (LEN) 是有前途的,但存在耐药性的风险. 需要策略来安全地管理LEN的停用.
科学领域:
- 药理学
- 病毒学
- 传染性疾病
背景情况:
- 口服预暴露预防 (PrEP) 是有效的,但坚持挑战需要新的选择.
- 可以注射的莱纳卡巴维尔 (LEN) 是一种长效的HIV预防策略,临床试验显示其潜力.
- 由于LEN的长期存在,人们担心在停止治疗后会出现抗药性.
研究的目的:
- 为LEN开发一个药理动力学模型.
- 量化LEN对野生型和耐药HIV菌株的预防效果.
- 评估在停止LEN注射后出现新药耐药性的风险.
主要方法:
- 对LEN的综合药理动力学 (PK/PD) 建模.
- 对各种艾滋病毒菌株的95%预防性血度 (EC95) 的估计.
- 基于LEN度衰减的耐药性风险的模拟.
主要成果:
- 在高于10 ng/ ml的度下,LEN证明对野生型HIV的完全保护.
- 需要更高的度来防止特定的LEN耐药突变物 (例如Q67H+N74D的85 ng/mL).
- 当LEN水平降至10 ng/ ml以下时,不同突变的时间窗口为79至201天时,发现了新的抗药性出现的重大风险.
结论:
- 长效的LEN注射剂可提供有效的HIV预防.
- 药物中断后出现抗药性的风险需要谨慎的管理策略.
- 需要进一步的研究来优化LEN剂量和停药方案,以减轻耐药性风险.
更多相关视频
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
272
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
272
Retrovirus Life Cycles
46.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.7K
Pharmacokinetics: Overview
7.1K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
7.1K
Pharmacodynamics: Overview and Principles
2.0K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.0K
Factors Influencing Drug Absorption: Presystemic Elimination
335
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
335


